№ lp_2_3_40595
File format: docx
Character count: 22944
File size: 75 KB
This document is a survey for hospitals regarding their Pediatric Pulmonology and Lung Surgery programs, including data collection on staff, clinical protocols, and patient care procedures.
Note:
Year
Theme:
Pediatric Pulmonology and Lung Surgery
Document Type:
Survey
Target Audience:
Hospitals, Pediatric Pulmonology Programs
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Document Type:
Collection of scientific abstracts
Language:
English
Thematic Areas:
Neurology; Dentistry; Pulmonology; Cardiology; Physiotherapy; Medical Imaging; Clinical Case Reports
Study Designs:
Observational study; case reports; review article; cohort study
Methods Mentioned:
Magnetic resonance imaging; image segmentation; statistical analysis; random forest classification; clinical management protocol; axial tomography; electromyographic recording; invasive coronary physiological assessment
Translator:
Alexander Frometa
Institution:
Grupo de traducciones Dpt. De servicios especiales de información CNICM-IMFOMED
Year:
2023
Region / city:
UK
Theme:
Oncology, Lung Cancer, Treatment Guidelines
Document type:
Clinical guidelines
Organization / institution:
NICE
Author:
NICE
Target audience:
Healthcare professionals
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Contextual description:
Detailed clinical guidelines outlining the recommended systemic treatments for advanced non-small-cell lung cancer based on disease progression and previous therapies.
Service:
Lung Cancer Whole Pathway
Document type:
Commissioning guidance
Health system:
NHS England
Period:
2024/25
Date of review:
April 2026
Scope:
Direct and specialised commissioning
Clinical focus:
Lung cancer
Geographical context:
United Kingdom
Policy context:
NHS Long Term Plan
Related pathway:
National Optimal Lung Cancer Pathway
Commissioning themes:
Early diagnosis, reducing variation, living with cancer
Evidence base:
NICE guidance and national standards
Note:
Year
Topic:
Lung disease, steroid treatment
Document type:
Information sheet
Organization / institution:
Sheffield Teaching Hospitals NHS Foundation Trust
Author:
Respiratory and endocrinology teams
Target audience:
People with lung disease on high dose inhaled steroids
Year:
2025
Region / City:
Shropshire, Telford and Wrekin
Subject:
Targeted Lung Healthcare Checks (TLHC), Procurement Process, NHS Contract Award
Document Type:
Panel Review
Organization:
NHS Shropshire, Telford and Wrekin Integrated Care Board (STW ICB)
Author:
Independent Patient Choice and Procurement Panel
Target Audience:
Healthcare providers, stakeholders in public sector procurement, regulatory bodies
Period of Validity:
1 March 2025 - 28 February 2027 (contract term, with extension option)
Approval Date:
25 November 2024
Amendment Date:
21 March 2025
Year:
2024/25
Region / City:
UK
Topic:
Lung Cancer Pathway
Document Type:
Commissioning Guidance
Author:
Not specified
Target Audience:
Healthcare professionals, commissioners, and providers in the NHS
Period of Validity:
2024/25
Approval Date:
Not specified
Review Date:
April 2025
Year:
2025
Program name:
DataLung – DZL Data Science School for Lung Researchers
Organization:
Deutsches Zentrum für Lungenforschung (DZL)
Target group:
DZL Academy fellows in lung research
Eligibility requirements:
Basic Python skills or numerical background depending on track; lung-related research project
Program tracks:
BioTrack; CompuTrack
Application deadline:
February 21, 2025
Notification date:
March 18, 2025
Contract requirement:
Employment contract valid until April 2027
Key dates:
April 14–16, 2025; October 13–17, 2025; October–December 2025
Locations:
Schloß Rauischholzhausen; Munich; virtual
Application materials:
CV/Biosketch; research project description; computational track record
Submission method:
Email submission with supervisor consent
Contact email:
[email protected]
Source type:
Call for applications for an academic training program
Year:
2021
Region / city:
Australia
Topic:
Oncology / Pharmaceutical
Document Type:
Submission
Agency:
Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
AstraZeneca Pty Ltd
Target Audience:
Medical professionals, regulatory authorities
Validity Period:
2021-2026
Approval Date:
20 April 2021
Modification Date:
Not specified
Year:
2023
Region / City:
Australia
Topic:
Oncology, Pharmaceutical Submission
Document Type:
Pharmaceutical Resubmission
Organization:
AstraZeneca Pty Ltd
Author:
Not specified
Target Audience:
Medical Practitioners
Period of Validity:
Ongoing
Approval Date:
Not specified
Date of Changes:
Not specified
Context:
A pharmaceutical resubmission document outlining the use of osimertinib as a first-line treatment for locally advanced or metastatic EGFRm non-small cell lung cancer (NSCLC) in Australia, including previous PBAC considerations and clinical trial data.
Year:
2016
Region / city:
New Zealand
Topic:
Lung Cancer, Healthcare Services
Document type:
Standards/Guidelines
Institution:
Ministry of Health
Author:
National Lung Cancer Working Group
Target audience:
Healthcare professionals, primary care providers, policymakers
Effective period:
2016
Approval date:
2016
Amendment date:
2016
ISBN:
978-0-947515-12-6
Language:
English
Year:
2023
Region / City:
N/A
Topic:
Lung Cancer Treatment, Immunotherapy
Document Type:
Research Paper
Author:
Ayush Chalishajar
Target Audience:
Researchers, Medical Professionals, Academics
Period of Action:
January 15th - March 19th
Approval Date:
N/A
Date of Changes:
N/A
Year:
2019
Region / city:
Australia
Topic:
Oncology, Lung Cancer Management
Document Type:
Educational Course
Organization:
Cancer Australia, eviQ Education
Author:
Cancer Australia
Target Audience:
Health professionals working in the oncology setting or involved in the care of lung cancer patients
Action Period:
May 2019 – May 2020
Approval Date:
Not specified
Date of Changes:
Not specified
Project Phases:
Stage 1 (sections 1-3), Stage 2 (sections 4-5), Stage 3 (sections 6-8)
Clinical Advisory Committee:
Yes
External Review Group:
Yes
Course Format:
eLearning series
Content Areas:
Prevention, Screening, Diagnosis, Treatment, Symptoms Management, End of Life Care, Survivorship
Time Frames:
Estimated start and end dates for stages, review periods for committees
Contact Information:
[email protected]
Expressions of interest closing date:
May 26
Year:
2026
Region / city:
Chermside, Queensland, Australia
Theme:
Lung cancer research, biorepository
Document type:
Research article
Organization / institution:
UQ Thoracic Research Centre, The Prince Charles Hospital
Author:
Anita Goldsworthy, Kelly Chee, Linda Passmore, Jaccalyne Brady, Barbara Page, Maria Martins, Edward Stephens, Caeli Zahra, Edwina Duhig, Ian Yang, Henry Marshall, Justin Tan, Morgan Windsor, Rishendran Naidoo, David Godbolt, Kwun M Fong
Target audience:
Researchers, clinicians, cancer specialists
Action period:
Ongoing
Approval date:
Not specified
Date of changes:
Not specified
Year:
2026
Region / city:
Not specified
Topic:
Toxicity, drug efficacy
Document type:
Scientific figure
Organization / institution:
Not specified
Author:
Not specified
Target audience:
Researchers, scientists
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Date of decision to refer:
${createdDate}
Note:
Date referral received at Trust
Hospital selection:
University Hospital Dorset (UHD), Dorset County Hospital (DCH), Salisbury NHS Foundation Trust
Surname:
${surname}
First Name:
${firstname}
Title:
${title}
Sex assigned at birth:
${gender}
Gender Identity:
${genderIdentity}
DOB:
${dob}
NHS Number:
${nhsNumber}
Ethnicity:
${ethnicity}
Patient Address:
${patientAddress}
Postcode:
${postcode}
Contact numbers:
Home: ${home}, Mobile: ${mobile}, Preferred phone number: ${preferredPhoneNumber}, Email: ${email}
Registered GP Name:
${usualName}
Practice Name:
${practiceName}
Direct line to the practice:
${bypass}
Main:
${main}
Fax:
${fax}
Email:
${gpEmail}
Referring Clinician:
${referringClinical}
Please include smoking status, history, and duration of symptoms:
${symptomsAndExaminationFindings}
Platelets:
${fbcG}
Calcium:
${calcium}
Clotting:
${clottingG}
Bone profile:
${boneProfileG}
LFTs:
${lftG}
U&Es (inc. eGFR):
${renalFunctionG}
Chest x-ray:
${chestXrayG}
Details of other significant medical history:
${medicalHistory}
Anticoagulation and/or antiplatelet medication:
${isAnticoagulatedWith}${antiPlatelets}${inr}
List or attach regular medication:
${medication}
Allergies:
${allergies}
Year:
2024
Note:
Region / city
Subject:
Oncology, Lung Cancer
Document Type:
Clinical Guidelines
Organization / Institution:
NICE
Target Audience:
Healthcare Professionals
Year:
2023
Region / City:
United States
Topic:
Pediatric Neurology/Neurosurgery Program Evaluation
Document Type:
Survey
Organization:
U.S. News & World Report
Author:
U.S. News & World Report
Target Audience:
Healthcare Providers, Pediatric Neurology/Neurosurgery Programs
Validity Period:
Current Year
Approval Date:
Not specified
Modification Date:
Not specified
Note:
Year
Region / City:
Massachusetts
Theme:
Tuberculosis Risk Assessment
Document Type:
User Guide
Organization / Institution:
Massachusetts Department of Public Health
Target Audience:
Healthcare providers, pediatricians